Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

Figure 3

Proportion of patients with total VA (Snellen) improvement, no change, or worsening in patients with at least 6 months of follow-up, in both (a) unilateral and (b) bilateral patients with DME. “Improvement” was defined as a decrease in the total visual acuity fraction denominator at considered visit versus baseline, “no change” as no difference in the total visual acuity fraction denominator at considered visit versus baseline, and “worsening” as an increase in the total visual acuity fraction denominator at considered visit versus baseline. DME, diabetic macular edema; VA, visual acuity.

(a) Unilateral DME

(b) Bilateral DME